Aclaris Therapeutics Inc is a biotechnology business based in the US. Aclaris Therapeutics shares (ACRS) are listed on the NASDAQ and all prices are listed in US Dollars. Aclaris Therapeutics employs 57 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $10.50 |
|---|---|
| 52-week range | $9.26 - $30.38 |
| 50-day moving average | $13.28 |
| 200-day moving average | $17.25 |
| Wall St. target price | $34.80 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.55 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.5 from 2022-01-25
| 1 week (2022-01-19) | 3.55% |
|---|---|
| 1 month (2021-12-22) | N/A |
| 3 months (2021-10-22) | N/A |
| 6 months (2021-07-26) | -30.56% |
| 1 year (2021-01-26) | -39.93% |
|---|---|
| 2 years (2020-01-24) | 568.79% |
| 3 years (2019-01-25) | 56.72% |
| 5 years (2017-01-26) | 27.04 |
| Revenue TTM | $6.8 million |
|---|---|
| Gross profit TTM | $-27,989,000 |
| Return on assets TTM | -21.71% |
| Return on equity TTM | -63.46% |
| Profit margin | 0% |
| Book value | $3.54 |
| Market capitalisation | $596.4 million |
TTM: trailing 12 months
We're not expecting Aclaris Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aclaris Therapeutics's shares have ranged in value from as little as $9.26 up to $30.375. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aclaris Therapeutics's is 0.4921. This would suggest that Aclaris Therapeutics's shares are less volatile than average (for this exchange).
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. .
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.